Protein Phosphatase 2A (PP2A or EC 18.104.22.168) - Pipeline Review, H2 2018
Protein Phosphatase 2A (PP2A or EC 22.214.171.124) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A - Pipeline Review, H2 2018, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Protein Phosphatase 2A (PP2A or EC 188.8.131.52) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Breast Tumor, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Renal Cell Carcinoma, Sarcomas, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Type 2 Diabetes, Ulcerative Colitis and Uveitis.
Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 184.108.40.206) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook